| P2093 | author name string | Awadhesh Kumar Singh | |
| | Ritu Singh | |
| P2860 | cites work | Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 |
| | Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 |
| | American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015 | Q28384855 |
| | Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis | Q33476850 |
| | Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial | Q33844615 |
| | Combination therapies with insulin in type 2 diabetes | Q34227542 |
| | Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes | Q34362258 |
| | Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes | Q34670462 |
| | Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 |
| | Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis | Q34985373 |
| | SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials | Q35181821 |
| | Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial | Q35225372 |
| | Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira). | Q35666228 |
| | A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine | Q35772593 |
| | Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). | Q36303786 |
| | Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight. | Q36357997 |
| | Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). | Q37106467 |
| | Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial | Q37279276 |
| | A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment | Q37319128 |
| | Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study | Q37331159 |
| | The continuation of oral medications with the initiation of insulin therapy in type 2 diabetes: a review of the evidence | Q37649386 |
| | Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions. | Q38264456 |
| | Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands | Q38441105 |
| | Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes | Q41621738 |
| | Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions | Q41959585 |
| | Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes | Q42688960 |
| | Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes | Q43187035 |
| | Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia | Q43275817 |
| | Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). | Q43869405 |
| | Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes | Q45250947 |
| | Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus | Q45350582 |
| | Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes | Q47581268 |
| | Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years | Q47871792 |
| | Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. | Q51321430 |
| | Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. | Q51359217 |
| | Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. | Q51359456 |
| | Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. | Q51361433 |
| | Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. | Q51362851 |
| | Effects of duration of type 2 diabetes mellitus on insulin secretion. | Q51491083 |
| | The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial. | Q53667132 |
| | Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes | Q57563922 |
| | Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes | Q59624449 |
| | Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase | Q85253126 |
| | Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy | Q87262274 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Insulin Therapy | Q2002370 |
| P304 | page(s) | 32-42 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Indian Journal of Endocrinology and Metabolism | Q15816442 |
| P1476 | title | Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review | |
| P478 | volume | 20 | |